Director, Chairman, Pres. & CEO · Phio Pharmaceuticals Corp. · Common Stock, $.0001 par value
Side
BUY
Value
$2,058
Shares
2,000
Price
$1.03
Executed
Sep 22, 2026
Disclosed
Sep 23, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 22 executedSep 23, 2026 disclosed
PHIO · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Bitterman Robert J filed this Form 4 reporting a open-market purchase of PHIO on Sep 22, 2026. It became public on Sep 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, Chairman, Pres. & CEO
Bitterman Robert Jcik:0001304395
Issuer
Phio Pharmaceuticals Corp.cik:0001533040
Revision history · 0
No field has changed since this record was first ingested.
